NL-OMON37071已完成不适用
A Phase I, open-label, randomized, 2-panel, sequential treatment study in healthy subjects to investigate the potential pharmacokinetic interactions between multiple doses of phenytoin or carbamazepine and telaprevir at steady-state - VX-950HPC1002
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 24
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 99（—）
入选标准
- •Each potential subject must satisfy all of the following criteria to be enrolled in the study.;- Be a man or woman 18 to 55 years of age, inclusive.;- If a woman, before entry she must be:;• postmenopausal for at least 2 years (amenorrheal for at least 3 years), OR;• surgically sterile (have had a total hysterectomy or bilateral oophorectomy, tubal ligation/bilateral tubal clips without reversal operation, or otherwise be incapable of becoming pregnant).;- Non-smoking for at least 3 months prior to selection, to be confirmed by a nicotine screening test according to the local standard of care.
排除标准
- •- Subjects of Asian ancestry, or previous identification as a positive carrier of the human leukocyte antigen (HLA) -B*1502.;- Hepatitis A, B or C or human immunodeficiency virus-type 1 or 2 (HIV-1 or HIV-2) infection at screening.
研究者
相似试验
进行中（未招募）
1 期
A study investigating the safety, absorption and elimination of 2 formulations of Bosutinib, a drug in the treatment of chronic myeloid leukemia.EUCTR2020-002782-34-NLPfizer Inc.66
进行中（未招募）
1 期
A study in healthy volunteers to look at how the test medicine, COMP360, is taken up by the body when given as two different strength capsulesTreatment-resistant depressionISRCTN16636661COMPASS Pathfinder Limited14
已完成
不适用
A phase 1, open-label, randomized, 2-period, 2-sequence, crossover study to evaluate the bioequivalence of Bosutinib pediatric capsule and the commercial tablet formulations in healthy participants under fed conditiochronic myeloid leukemia10024324NL-OMON49458Pfizer, Inc.66
已完成
不适用
A phase I, open-label, randomized, two period, two-way cross over study to assess the influence of a high-calorie, high fat meal on the bioavailability of a 40 mg extended release PHA 022121 oral formulatioangioedemaNL-OMON53489Pharvaris Netherlands BV10
已完成
不适用
A phase 1, open-label, non-randomized, 2-period, fixed sequence study to investigate the absorption, distribution, metabolism and excretion of 14C-PF-06651600 and to assess the absolute bioavailability and fraction absorbed of PF-06651600 in healthy male participants using a 14C-microtracer approachNL-OMON48152Pfizer, Inc.6